Opferman JT - Search Results

1

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.

Koss B, Ryan J, Budhraja A, Szarama K, Yang X, Bathina M, Cardone MH, Nikolovska-Coleska Z, Letai A, Opferman JT. Koss B, et al. Among authors: opferman jt. Oncotarget. 2016 Mar 8;7(10):11500-11. doi: 10.18632/oncotarget.7204. Oncotarget. 2016. PMID: 26862853 Free PMC article.

2

Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Opferman JT, et al. Nature. 2003 Dec 11;426(6967):671-6. doi: 10.1038/nature02067. Nature. 2003. PMID: 14668867 Free article.

3

MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts.

Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A. Brunelle JK, et al. Among authors: opferman jt. J Cell Biol. 2009 Nov 2;187(3):429-42. doi: 10.1083/jcb.200904049. Epub 2009 Oct 26. J Cell Biol. 2009. PMID: 19948485 Free PMC article.

4

Ubiquitin-independent degradation of antiapoptotic MCL-1.

Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT. Stewart DP, et al. Among authors: opferman jt. Mol Cell Biol. 2010 Jun;30(12):3099-110. doi: 10.1128/MCB.01266-09. Epub 2010 Apr 12. Mol Cell Biol. 2010. PMID: 20385764 Free PMC article.

5

Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration.

Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, Youle RJ, Green DR, Opferman JT. Perciavalle RM, et al. Among authors: opferman jt. Nat Cell Biol. 2012 Apr 29;14(6):575-83. doi: 10.1038/ncb2488. Nat Cell Biol. 2012. PMID: 22544066 Free PMC article.

6

A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.

Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, Opferman JT, Walensky LD. Cohen NA, et al. Among authors: opferman jt. Chem Biol. 2012 Sep 21;19(9):1175-86. doi: 10.1016/j.chembiol.2012.07.018. Chem Biol. 2012. PMID: 22999885 Free PMC article.

7

Mcl-1 antagonizes Bax/Bak to promote effector CD4(+) and CD8(+) T-cell responses.

Tripathi P, Koss B, Opferman JT, Hildeman DA. Tripathi P, et al. Among authors: opferman jt. Cell Death Differ. 2013 Aug;20(8):998-1007. doi: 10.1038/cdd.2013.25. Epub 2013 Apr 5. Cell Death Differ. 2013. PMID: 23558951 Free PMC article.

8

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction.

Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT. Wang X, et al. Among authors: opferman jt. Genes Dev. 2013 Jun 15;27(12):1351-64. doi: 10.1101/gad.215855.113. Genes Dev. 2013. PMID: 23788622 Free PMC article.

9

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.

Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE, Williams RT, Opferman JT. Koss B, et al. Among authors: opferman jt. Blood. 2013 Aug 29;122(9):1587-98. doi: 10.1182/blood-2012-06-440230. Epub 2013 Jul 23. Blood. 2013. PMID: 23881917 Free PMC article.

10

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K. Fan F, et al. Among authors: opferman jt. Cancer Lett. 2014 Feb 28;343(2):286-94. doi: 10.1016/j.canlet.2013.09.042. Epub 2013 Oct 8. Cancer Lett. 2014. PMID: 24120758

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters